BRIEF published on 10/30/2025 at 21:05, 1 month 5 days ago TME Pharma's Semi-Annual Report and Financial Restructuring Financial Results Biotechnology CEO Appointment Bond Issuance TME Pharma
PRESS RELEASE published on 10/30/2025 at 21:00, 1 month 5 days ago TME Pharma publishes its semi annual results and half-year report TME Pharma publishes semi annual results and half-year report showing cost reductions, new CEO, and fundraising activities. Focus on NOX-A12 and NOX-E36 assets Fundraising Cost Reductions TME Pharma NOX-A12 Semi Annual Results
PRESS RELEASE published on 09/01/2025 at 08:45, 3 months 3 days ago Inside Information: Other news releases TME Pharma completes August financing, with €500k cash received on August 28th, bringing cash position to €2.35M. Organization aims to attract financing for cancer and eye therapies Cash Position TME Pharma August Financing Cost-efficient Organization Novel Therapies
BRIEF published on 09/01/2025 at 08:45, 3 months 3 days ago TME Pharma successfully completes its August fundraising round Biotechnology Fundraising Treasury Cryptocurrencies Cancer
BRIEF published on 08/25/2025 at 08:05, 3 months 10 days ago TME Pharma Secures €500,000 through New Bond Issue Investment Strategy Cost Reduction Bond Issuance Financial Strategy Shareholder Commitments
PRESS RELEASE published on 08/25/2025 at 08:00, 3 months 10 days ago Inside Information / Other news releases TME Pharma to raise €500k through bond issue & receives new shareholding notice. CEO & Chairman also invest. Funds to boost financial position & support R&D projects & investment strategy Fundraising Shareholding CEO Bond Issue TME Pharma
BRIEF published on 07/08/2025 at 08:05, 4 months 27 days ago TME Pharma Terminates Liquidity Contract Amid Cost Optimization Liquidity Contract Biotechnology Refinancing Cost Optimization TME Pharma
PRESS RELEASE published on 07/08/2025 at 08:00, 4 months 27 days ago Inside Information / Other news releases TME Pharma terminates liquidity contract with Invest Securities to optimize costs. Improve trading volume of shares and healthy liquidity deemed contract unnecessary. Finds success in refinancing and reducing operational costs Liquidity Contract Cost Optimization Trading Volume Organizational Restructuring TME Pharma
BRIEF published on 05/21/2025 at 08:05, 6 months 14 days ago TME Pharma Enhances Financial Outlook with €1.7M Bond Commitments Strategic Partnerships Bond Issuance Clinical Programs Financial Visibility Cost Structure
PRESS RELEASE published on 05/21/2025 at 08:00, 6 months 14 days ago Inside Information / Other news releases TME Pharma extends financial visibility to May 2026 by securing €1.7M financing through regular bonds with attached warrants. CEO and board show strong commitment to company's success Clinical Programs TME Pharma Financial Visibility Regular Bonds Private Warrants
Published on 12/05/2025 at 02:35, 2 hours 52 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 4 hours 27 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 22 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 6 hours 27 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 1 hour 57 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 5 hours 37 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 2 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 12 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 17 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 11 hours 27 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 11 hours 42 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 11 hours 43 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 26 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 11 hours ago Declaration of voting rights at the end of November 2025
